Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enno Schmidt

Showing results (241-250 of 348) with videos related to

Pageof 35
Sort By:
Nature Reviews. Disease Primers|March 3, 2025
Author Correction: Bullous pemphigoidHossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, et al.
The British Journal of Dermatology|February 27, 2026
Comparative performance of four immunoassays for anti-laminin 332 serum IgG in mucous membrane pemphigoid: a multicentre prospective blinded studyStephanie Goletz, Norito Ishii, Charlotte Kiehne, et al.
Orphanet Journal of Rare Diseases|May 15, 2015
Prevalence of pemphigus and pemphigoid autoantibodies in the general populationWiebke Prüßmann, Jasper Prüßmann, Hiroshi Koga, et al.
Nature Communications|September 13, 2024
Unbiased screening identifies regulators of cell-cell adhesion and treatment options in pemphigusHenriette Franz, Maitreyi Rathod, Aude Zimmermann, et al.
Journal of the American Academy of Dermatology|February 21, 2012
Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisitaLars Komorowski, Ralf Müller, Artem Vorobyev, et al.
Journal of Autoimmunity|September 18, 2012
Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra inductionUnni Krishna S R L Samavedam, Kathrin Kalies, Jürgen Scheller, et al.
Life (Basel, Switzerland)|February 26, 2025
Localization of Lesions in Autoimmune Blistering Diseases Is Independent of Site-Specific Target Antigen ExpressionTina Rastegar Lari, Louis Macias, Lara Robrahn, et al.
Health Technology Assessment (Winchester, England)|April 14, 2017
A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trialJoanne R Chalmers, Fenella Wojnarowska, Gudula Kirtschig, et al.
The Journal of Investigative Dermatology|November 18, 2021
Multiple Modes of Action Mediate the Therapeutic Effect of Intravenous IgG in Experimental Epidermolysis Bullosa AcquisitaElena Pipi, Anika Kasprick, Hiroaki Iwata, et al.
Lancet (London, England)|March 11, 2017
Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trialHywel C Williams, Fenella Wojnarowska, Gudula Kirtschig, et al.
Pageof 35

Showing results (241-250 of 348) with videos related to

Sort By:
Pageof 35
Nature Reviews. Disease Primers|March 3, 2025
Author Correction: Bullous pemphigoidHossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, et al.
The British Journal of Dermatology|February 27, 2026
Comparative performance of four immunoassays for anti-laminin 332 serum IgG in mucous membrane pemphigoid: a multicentre prospective blinded studyStephanie Goletz, Norito Ishii, Charlotte Kiehne, et al.
Orphanet Journal of Rare Diseases|May 15, 2015
Prevalence of pemphigus and pemphigoid autoantibodies in the general populationWiebke Prüßmann, Jasper Prüßmann, Hiroshi Koga, et al.
Nature Communications|September 13, 2024
Unbiased screening identifies regulators of cell-cell adhesion and treatment options in pemphigusHenriette Franz, Maitreyi Rathod, Aude Zimmermann, et al.
Journal of the American Academy of Dermatology|February 21, 2012
Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisitaLars Komorowski, Ralf Müller, Artem Vorobyev, et al.
Journal of Autoimmunity|September 18, 2012
Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra inductionUnni Krishna S R L Samavedam, Kathrin Kalies, Jürgen Scheller, et al.
Life (Basel, Switzerland)|February 26, 2025
Localization of Lesions in Autoimmune Blistering Diseases Is Independent of Site-Specific Target Antigen ExpressionTina Rastegar Lari, Louis Macias, Lara Robrahn, et al.
Health Technology Assessment (Winchester, England)|April 14, 2017
A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trialJoanne R Chalmers, Fenella Wojnarowska, Gudula Kirtschig, et al.
The Journal of Investigative Dermatology|November 18, 2021
Multiple Modes of Action Mediate the Therapeutic Effect of Intravenous IgG in Experimental Epidermolysis Bullosa AcquisitaElena Pipi, Anika Kasprick, Hiroaki Iwata, et al.
Lancet (London, England)|March 11, 2017
Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trialHywel C Williams, Fenella Wojnarowska, Gudula Kirtschig, et al.
Pageof 35